BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 19238077)

  • 21. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice.
    Rankin EB; Higgins DF; Walisser JA; Johnson RS; Bradfield CA; Haase VH
    Mol Cell Biol; 2005 Apr; 25(8):3163-72. PubMed ID: 15798202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance.
    Anlauf M; Perren A; Klöppel G
    Pathobiology; 2007; 74(5):279-84. PubMed ID: 17890894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms.
    Vortmeyer AO; Falke EA; Gläsker S; Li J; Oldfield EH
    Acta Neuropathol; 2013 Mar; 125(3):333-50. PubMed ID: 23400300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8 in von Hippel-Lindau disease-related lesions.
    Chatzopoulos K; Aubry MC; Gupta S
    Hum Pathol; 2022 May; 123():93-101. PubMed ID: 35196526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.
    Okumura F; Uematsu K; Byrne SD; Hirano M; Joo-Okumura A; Nishikimi A; Shuin T; Fukui Y; Nakatsukasa K; Kamura T
    Mol Cell Biol; 2016 Jun; 36(12):1803-17. PubMed ID: 27090638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of HIF-1 regulated proteins vascular endothelial growth factor, carbonic anhydrase IX and hypoxia inducible gene 2 in hemangioblastomas.
    Li M; Song J; Pytel P
    Folia Neuropathol; 2014; 52(3):234-42. PubMed ID: 25310734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.
    Raval RR; Lau KW; Tran MG; Sowter HM; Mandriota SJ; Li JL; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
    Mol Cell Biol; 2005 Jul; 25(13):5675-86. PubMed ID: 15964822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
    PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas.
    Henopp T; Anlauf M; Schmitt A; Schlenger R; Zalatnai A; Couvelard A; Ruszniewski P; Schaps KP; Jonkers YM; Speel EJ; Pellegata NS; Heitz PU; Komminoth P; Perren A; Klöppel G
    J Clin Endocrinol Metab; 2009 Jan; 94(1):213-7. PubMed ID: 18957496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.
    Pascal LE; Ai J; Rigatti LH; Lipton AK; Xiao W; Gnarra JR; Wang Z
    Angiogenesis; 2011 Sep; 14(3):331-43. PubMed ID: 21638067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Von Hippel-Lindau disease and endocrine tumour susceptibility.
    Woodward ER; Maher ER
    Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Action of hypoxia-inducible factor in liver and kidney from mice with Pax8-rtTA-based deletion of von Hippel-Lindau protein.
    Mathia S; Paliege A; Koesters R; Peters H; Neumayer HH; Bachmann S; Rosenberger C
    Acta Physiol (Oxf); 2013 Mar; 207(3):565-76. PubMed ID: 23384425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma.
    Ebru T; Fulya OP; Hakan A; Vuslat YC; Necdet S; Nuray C; Filiz O
    Int Braz J Urol; 2017; 43(3):440-454. PubMed ID: 27583351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of hepatic fibrosis by overexpression of von Hippel-Lindau protein in experimental models of chronic liver disease.
    Wang J; Lu Z; Xu Z; Tian P; Miao H; Pan S; Song R; Sun X; Zhao B; Wang D; Ma Y; Song X; Zhang S; Liu L; Jiang H
    Sci Rep; 2017 Jan; 7():41038. PubMed ID: 28112200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
    Kappler M; Taubert H; Holzhausen HJ; Reddemann R; Rot S; Becker A; Kuhnt T; Dellas K; Dunst J; Vordermark D; Hänsgen G; Bache M
    Strahlenther Onkol; 2008 Aug; 184(8):393-9. PubMed ID: 18956515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
    Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
    Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clear cell papillary renal cell carcinoma: a clinicopathological study emphasizing ultrastructural features and cytogenetic heterogeneity.
    Shi SS; Shen Q; Xia QY; Tu P; Shi QL; Zhou XJ; Rao Q
    Int J Clin Exp Pathol; 2013; 6(12):2936-42. PubMed ID: 24294381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor.
    Rankin EB; Tomaszewski JE; Haase VH
    Cancer Res; 2006 Mar; 66(5):2576-83. PubMed ID: 16510575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of VHL tumourigenesis in nerve root tissue.
    Vortmeyer AO; Tran MG; Zeng W; Gläsker S; Riley C; Tsokos M; Ikejiri B; Merrill MJ; Raffeld M; Zhuang Z; Lonser RR; Maxwell PH; Oldfield EH
    J Pathol; 2006 Nov; 210(3):374-82. PubMed ID: 16981244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
    Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
    Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.